Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 20, 2009

Ontario Institute for Cancer Research to Use Helicos’ Single Molecule Sequencing Technology

  • The Ontario Institute for Cancer Research (OICR) has purchased the Helicos™ Genetic Analysis System to study cancer genomics. This single molecule sequencing technology reportedly enables scientists to various studies without DNA ligation or amplification.

    Helicos Biosciences says that genetic analysis with this platform eliminates the biases, complexity, and errors introduced by DNA amplification, requires minute amounts of starting material, and provides the most direct and accurate view of biological samples.

    “The translational cancer research we are conducting at our center can benefit greatly from the advantages of single molecule sequencing,” believes Tom Hudson, president and scientific director of the OICR. “We hope to use this technology for the unbiased and comprehensive characterization of tumor samples to ultimately lead to discoveries that have a clinical impact.”

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »